Abzena, a Cambridge, UK-based global partnership research organization providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), raised $10M in growth funding.
Biospring Partners made the investment.
The company intends to use the new capital to accelerate its growth plans.
Led by Jonathan Goldman MD, CEO, Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK.